Showing results (81-90 of 111) with videos related to
Sort By:
Pageof 12
Biochemical and Biophysical Research Communications|March 16, 2005
Antiangiogenic activity of 11,11'-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicolaYi Chen, Yi-Xiang Zhang, Mei-Hong Li, et al.Molecular Pharmacology|June 27, 2006
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activitySmitha Antony, Keli K Agama, Ze-Hong Miao, et al.Cancer Research|November 3, 2007
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistanceSmitha Antony, Keli K Agama, Ze-Hong Miao, et al.International Journal of Cancer|January 25, 2019
Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicityHua-Dong Chen, Chuan-Huizi Chen, Yu-Ting Wang, et al.Acta Pharmacologica Sinica|August 4, 2017
Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacyWen-Hua Chen, Shan-Shan Song, Ming-Hui Qi, et al.Journal of Natural Products|September 1, 2018
Flabellipparicine, a Flabelliformide-Apparicine-Type Bisindole Alkaloid from Tabernaemontana divaricataYou-Sheng Cai, Ariel M Sarotti, Ting-Lan Zhou, et al.Life Sciences|February 27, 2025
The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expressionYing-Jie Ou, Ben-Jin Liu, Yi-Fei Xuan, et al.Neoplasia (New York, N.Y.)|July 30, 2022
SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapyLi-Na Zhou, Chaodong Xiong, Yong-Jun Cheng, et al.European Journal of Medicinal Chemistry|July 5, 2022
Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactoneMuzaffar Kayumov, Li Jia, Azizbek Pardaev, et al.Journal of Medicinal Chemistry|February 4, 2025
Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 InhibitorsJunjie Zhang, Benjin Liu, Ruyue Ren, et al.Pageof 12